Clinical and Molecular Hepatology

Article	Citations
Preface	441
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign	390
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	266
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	209
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus	188
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?	134
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity	123
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	104
Approaches to quantifying hepatitis B virus covalently closed circular DNA	97
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer	95
Letter"Novel Genetic Modulators of MASLD Identified Through Genome-Wide Interaction with BMI"	90
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation	88
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis	81
Contemporary Trends in Extrahepatic Mortality of Chronic Liver Disease in the United States from 2014 to 2023	75
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)	71
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases	68
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials	68
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A	66
Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”	66
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study	61
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target	59
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease	57
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c	54
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	54
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis	54

Liver organoids: Current advances and future applications for hepatology	52
Toward hepatitis C virus elimination using artificial intelligence	52
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma	50
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	50
HCC Surveillance After Curative Treatment: A New Frontier for Abbreviated MRI Editorial on: “Non-contrast MRI for Detection of Late Recurrent Hepatocellular Carcinoma After Curative Treatment: Compari	47
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma	47
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma	44
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023	43
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial	43
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	42
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe	41
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate	41
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs	40
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?	40
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	39
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review	39
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	39
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment	38
Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation	38
What is new in the 2024 Chinese guidelines for fatty liver disease?	37
Correspondence to the letter titled “Revisiting the Role of Non-Contrast MRI in Recurrent HCC: Bridging Diagnostic Performance and Real-World Applicability”	36
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	36
A decade of liver organoids: Advances in disease modeling	36
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program	35
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease	34
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”	34
Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”	34
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality	34
Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	33
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”	32
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies	31
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma	30
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly	30
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study	29
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated	29
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	29
Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C	29
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies	28
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?	28
Immunopathogenesis of liver fibrosis in steatotic liver disease	28
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”	27
Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhib	26
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”	26
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The	25
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways	25
Acute-on-chronic liver failure: Terminology, mechanisms and management	25
Metabolic Health in Antiviral Era of Chronic Hepatitis B	24
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression	24
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?	24
Interaction between sarcopenia and nonalcoholic fatty liver disease	24

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity	23
Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score? Editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dys	23
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences	23
Global incidence and prevalence of nonalcoholic fatty liver disease	23
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohe	23
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis	23
Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load	23
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma	23
A new Korean nomenclature for steatotic liver disease	22
Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”	22
Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	22
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients	22
Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis	22
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma	21
Mendelian randomization does not support the effects of G CSF on decompensated liver disease	21
Gut microbiome and metabolome signatures in liver cirrhosis-related complications	20
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?	20
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association	20
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”	20
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma	20
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise	20
Regulation of Hepatitis B Virus cccDNA by Metabolic Pathways	19
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy	19
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”	19
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation	19
Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	19
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati	19
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial	19
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with	18
Screening strategy for non-alcoholic fatty liver disease	18
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma	18
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	18
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications	17
KASL clinical practice guidelines for management of chronic hepatitis B	17
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	17
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	17
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	17
A non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: the Baveno VI-SSM combined model.	16
JCAD, a new potential therapeutic target in cholestatic liver disease	16
Evidence-based hyponatremia management in liver disease	16
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”	16
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey	16
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	16
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients	15
Reply to correspondence on “A Novel Link Between Tumor Cell Metabolism and Patient Prognosis: Editorial on ‘Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and On	15
Clinical implications of residual changes following HCV clearance	15
Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications	15
Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	15
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease	15
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences	15
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	14
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	14
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues	14
Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline	14
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by	14
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes	14
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic	14
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agon	14
Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open	13
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review	13
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	13
Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatiti	13
Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma	13
Roles of X-box binding protein 1 in liver pathogenesis	13
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization	13
Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”	13
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs	13
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	13
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults	12
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	12
Management of refractory ascites	12
Recent advances in nonalcoholic fatty liver disease metabolomics	12
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance	12
Non-alcoholic fatty liver disease: Definition and subtypes	12
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and	12
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma developme	11
Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]	11
Acute hepatitis C virus infection: clinical update and remaining challenges	11
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”	11
Congratulatory remarks	11

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”	11
Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunctionassociated steatotic liver disease”: Rethinking first-line screening in MASLD: beyond the limitations of Fi	11
Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”	11
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults	11
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis	11
History and future of hepatitis B virus control in South Korea	11
Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer	10
Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”	10
Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”	10
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters	10
The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on “Ischemia-free liver transplantation improves the prog	10
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis	10
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD	9
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles	9
Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma	9
Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	9
Hepatorenal syndrome: Current concepts and future perspectives	9
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives	9
Re: “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	9
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	9
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation	9
The latest global burden of liver cancer: A past and present threat	9